KBTBD4 Inhibitors
KBTBD4 inhibitors encompass a range of compounds that, while not directly targeting KBTBD4, can indirectly inhibit its activity by modulating the ubiquitin-proteasome system (UPS). These inhibitors work by hindering the degradation of ubiquitinated proteins, which results in an accumulation of ubiquitin-tagged substrates in the cell. This accumulation ramps up the competition for KBTBD4, as the enzyme's substrate-binding capacity can become saturated. When proteasome inhibitors like Bortezomib, Carfilzomib, or Oprozomib are in play, the UPS is disrupted, leading to elevated levels of ubiquitinated proteins. KBTBD4, which has roles in binding to these proteins, is then indirectly inhibited due to the overstressed system, which limits its ability to interact with its intended targets. The increase in ubiquitinated proteins can also affect the enzyme's selectivity, as it may not be able to differentiate between substrates effectively under these competitive conditions.
In addition to proteasome inhibitors, compounds like PR-619 and PYR-41, which are deubiquitinase and E1 enzyme inhibitors respectively, also indirectly impede KBTBD4 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that prevents the degradation of ubiquitinated proteins, leading to the accumulation of these proteins in the cell. This can indirectly inhibit KBTBD4 by overwhelming its capacity to bind substrates due to the increased competition for binding. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Irreversible proteasome inhibitor that leads to the accumulation of ubiquitinated proteins. Similar to Bortezomib, it can indirectly inhibit KBTBD4 by increasing the substrate competition, thereby limiting its functional activity on specific substrates. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oral proteasome inhibitor that causes an accumulation of ubiquitinated proteins, potentially inhibiting KBTBD4 indirectly by the same mechanism as Bortezomib and Carfilzomib, through increased competition for substrate binding. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Reversible proteasome inhibitor that can lead to an increase in ubiquitinated proteins, which may indirectly inhibit KBTBD4 by saturating its substrate-binding capacity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Selective and irreversible proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, potentially inhibiting KBTBD4 indirectly via heightened substrate competition. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Specific inhibitor of the proteasome that causes an increase in ubiquitinated proteins, which could indirectly inhibit KBTBD4 by reducing its ability to bind and process substrates due to the competitive environment. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor that can lead to increased levels of ubiquitinated proteins, potentially inhibiting KBTBD4 indirectly by the same mechanism of increased competition for substrates. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Natural compound that can disrupt the proteasomal pathway by inhibiting the 20S proteasome, leading to indirect inhibition of KBTBD4 by increasing ubiquitinated proteins that compete for binding. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $75.00 $184.00 $423.00 | 1 | |
Broad-spectrum deubiquitinase inhibitor that could lead to the accumulation of ubiquitinated proteins, thereby indirectly inhibiting KBTBD4 through elevated substrate competition. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Irreversible inhibitor of ubiquitin-activating enzyme E1. By preventing ubiquitin conjugation, it could lead to reduced substrate ubiquitination, indirectly affecting KBTBD4's ability to bind and process ubiquitinated substrates. | ||||||